Carregando
AbbVie’s anti-inflammatory blockbuster Humira (adalimumab) used to be one of the top-selling drugs worldwide, with the drug generating $21.2bn in sales in its last year of market exclusivity in 2023. Whilst still a heavyweight in the monoclonal antibody arena, revenue
Recent Comments
Olá, mundo!
Um comentarista do WordPressHear from our Customer Community
Fletch Skinner